• Thurs news: AbbVie Parkinson’s drug. Arch raises $3B biotech fund. Biogen dropping failed Sage tremor drug. AZ gets sought-after Tagrisso OK. Pfizer withdrawing sickle cell med. See more on our front page

Pfizer Where Are You?

anonymous

Guest
AZ missed its best opportunity with Pfizer. It's awful here with a revolving door with managers and the ones that stay should be fired. Micro managing at a whole new level. Have to wonder why they are no longer reps as they interfere constantly.
 

<



yeah, right. But hey, on the other side, they would get a great bargain basement deal vs 2014. AZ won't allow a second go around to go unnoticed. Any offers to buy AZ should be seriously entertained.
 




yeah, right. But hey, on the other side, they would get a great bargain basement deal vs 2014. AZ won't allow a second go around to go unnoticed. Any offers to buy AZ should be seriously entertained.
Pfizer has to be thanking God for the AZ deal not going thru. We will probably end up being taken over by some Generic company.
 








yeah, right. But hey, on the other side, they would get a great bargain basement deal vs 2014. AZ won't allow a second go around to go unnoticed. Any offers to buy AZ should be seriously entertained.

Merck is our only hope as shareholders. As employees, we will all be fired. We do not stand a chance in Wilmington.
 








Looking more and more likely everyday here in Wilmington. There are a lot of meetings going on behind closed doors and many off site meetings too.

Earning miss for Q3. How Finance books Merck cash and Aspen cash will make it appear as if earnings expectations were exceeded. Don't be fooled by fuzzy finance.
 
























Similar threads